Back to top
more

Nicox (NICXF)

(Delayed Data from OTC)

$0.44 USD

0.44
NA

0.00 (0.00%)

Updated Dec 28, 2023 12:11 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for NICXF

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Nicox SA [NICXF]

Reports for Purchase

Showing records 61 - 80 ( 119 total )

Company: Nicox SA

Industry: Medical - Biomedical and Genetics

Record: 61

04/21/2021

Company Report

Pages: 7

1Q21 Financial Highlights Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Nicox SA

Industry: Medical - Biomedical and Genetics

Record: 62

04/19/2021

Company Report

Pages: 7

VYZULTA Receives Brazilian Regulatory Approval; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Nicox SA

Industry: Medical - Biomedical and Genetics

Record: 63

03/24/2021

Company Report

Pages: 6

Phase 3 Glaucoma Trial Reaches 50% Enrollment Milestone; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Nicox SA

Industry: Medical - Biomedical and Genetics

Record: 64

03/09/2021

Company Report

Pages: 6

No surprises as NCX-470 Phase III trials advance

Provider: Edison Investment Research Limited

Analyst: HEMAMI P

Price: .00

Research Provided by a Third Party

Company: Nicox SA

Industry: Medical - Biomedical and Genetics

Record: 65

03/05/2021

Company Report

Pages: 6

Phase 3 Denali Trial Authorized to Proceed in China; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Nicox SA

Industry: Medical - Biomedical and Genetics

Record: 66

03/02/2021

Company Report

Pages: 7

2020 Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Nicox SA

Industry: Medical - Biomedical and Genetics

Record: 67

02/24/2021

Company Report

Pages: 6

Theravance Announces Promising TD-0903 Data in COVID-19 Study on 4Q Call; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Nicox SA

Industry: Medical - Biomedical and Genetics

Record: 68

02/16/2021

Company Report

Pages: 7

ZERVIATE U.S. Promotion Expanded; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Nicox SA

Industry: Medical - Biomedical and Genetics

Record: 69

02/10/2021

Company Report

Pages: 7

VYZULTA Secures Regulatory Approval in South Korea; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Nicox SA

Industry: Medical - Biomedical and Genetics

Record: 70

01/21/2021

Company Report

Pages: 7

4Q20 Financial Highlights Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Nicox SA

Industry: Medical - Biomedical and Genetics

Record: 71

01/21/2021

Company Report

Pages: 17

Focus on sight - Initiation of coverage

Provider: Edison Investment Research Limited

Analyst: HEMAMI P

Price: .00

Research Provided by a Third Party

Company: Nicox SA

Industry: Medical - Biomedical and Genetics

Record: 72

12/31/2020

Company Report

Pages: 6

First Patient Dosed in ZERVIATE China Phase 3 Trial; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Nicox SA

Industry: Medical - Biomedical and Genetics

Record: 73

12/23/2020

Company Report

Pages: 7

VYZULTA Secures Regulatory Approval in Colombia; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Nicox SA

Industry: Medical - Biomedical and Genetics

Record: 74

12/16/2020

Company Report

Pages: 6

NCX 4251 Phase 2b Blepharitis Trial Starts Patient Enrollment; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Nicox SA

Industry: Medical - Biomedical and Genetics

Record: 75

12/14/2020

Company Report

Pages: 6

Naproxcinod Potential in COVID-19 Therapy; Financing Done; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Nicox SA

Industry: Medical - Biomedical and Genetics

Record: 76

11/23/2020

Company Report

Pages: 6

VYZULTA Launched in Argentina; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Nicox SA

Industry: Medical - Biomedical and Genetics

Record: 77

11/11/2020

Company Report

Pages: 6

Second NCX 470 Phase 3 Glaucoma Trial Initiated on Schedule; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Nicox SA

Industry: Medical - Biomedical and Genetics

Record: 78

10/30/2020

Company Report

Pages: 5

European Patent Granted for NCX 470; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Nicox SA

Industry: Medical - Biomedical and Genetics

Record: 79

10/27/2020

Company Report

Pages: 5

NCX 470 Phase 3 Trial Permitted to Start in China; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Nicox SA

Industry: Medical - Biomedical and Genetics

Record: 80

10/26/2020

Company Report

Pages: 6

New Class of Nitric Oxide-Donating Agent for Glaucoma Selected; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party